An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901

Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the w...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Robert Janssen, I-Feng Lin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2022-04-01
Colecção:	Vaccines
Assuntos:	immunobridging MVC-COV1901 ChAdOx nCOV-19 neutralizing antibodies
Acesso em linha:	https://www.mdpi.com/2076-393X/10/5/655
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!